Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118245 | 0.85 | SLC9A1 (0.40) | SLC9A1CA1CA2CA4CA7 | |
| SCHEMBL3115343 | 0.85 | GAA (0.40) | SLC9A1CA1CA2CA4CA7 | |
| SCHEMBL3118241 | 0.85 | SLC9A1 (0.40) | SLC9A1CA1CA2CA4CA7 | |
| SCHEMBL3115335 | 0.85 | GAA (0.40) | SLC9A1CA1CA2CA4CA7 | |
| SCHEMBL3118234 | 0.85 | SLC9A1 (0.40) | SLC9A1CA1CA2CA4CA7 | |
| SCHEMBL3115351 | 0.85 | GAA (0.40) | SLC9A1CA1CA2CA4CA7 | |
| SCHEMBL7226907 | 0.84 | MCL1 (0.50) | MCL1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7226904 | 0.84 | MCL1 (0.50) | MCL1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3113860 | 0.81 | SLC9A1 (0.42) | SLC9A1CA1CA2CA4CA7 | |
| SCHEMBL6832060 | 0.78 | SLC9A1 (0.60) | SLC9A1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700778-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1385506-B1 | ACYLATED PIPERIDINE DERIVATES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7012084-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20060025442-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| US-20040092501-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025442-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | SLC9A1 4237/4885CA1 4882/4885CA2 4769/4885 |
| US-20040092501-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | SLC9A1 4237/4885CA1 4882/4885CA2 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.